Kepler Capital Markets set a €62.00 ($72.09) price target on Gerresheimer (ETR:GXI) in a research note issued to investors on Friday. The brokerage currently has a sell rating on the stock.
Other equities analysts have also issued reports about the company. DZ Bank reaffirmed a buy rating on shares of Gerresheimer in a research report on Thursday, July 12th. Berenberg Bank set a €78.00 ($90.70) price target on Gerresheimer and gave the company a buy rating in a research report on Tuesday, July 10th. Credit Suisse Group set a €72.00 ($83.72) price target on Gerresheimer and gave the company a buy rating in a research report on Monday, July 9th. Finally, Deutsche Bank set a €77.00 ($89.53) price target on Gerresheimer and gave the company a buy rating in a research report on Tuesday, June 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of €71.67 ($83.33).
Shares of ETR:GXI traded down €2.85 ($3.31) during trading on Friday, reaching €61.50 ($71.51). 389,276 shares of the stock were exchanged, compared to its average volume of 140,925. Gerresheimer has a 1-year low of €59.97 ($69.73) and a 1-year high of €78.25 ($90.99).
Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, including inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for the pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.
See Also: Hedge Funds Explained
Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.